Mark R. Gilbert, M.D.
Deputy Chief
Terri S. Armstrong, Ph.D.
Building 82, Room 225
Bethesda, MD 20892-8202

Neuro-Oncology Clinic at NIH

Dr. Jing WuSpecial Update

Our Neuro-Oncology Clinic is changing normal operating procedures due to the novel coronavirus (COVID-19). 

  • If you are scheduled for an appointment within the next 30 days, you will receive a phone call from a patient care coordinator or health care provider to discuss your visit and what to expect.
  • If you need to schedule an appointment, your health care provider should contact us first.

Your care and safety remain our top priority and we appreciate your understanding during this time of continuous change. You can contact us at or 240-760-6010 with your questions or concerns.

Follow @NIHBrainTumor for updates.  

- Posted March 20, 2020

The Neuro-Oncology Clinic is comprised of a multidisciplinary team of physicians, other healthcare providers, and scientists who are dedicated to developing new therapies and improving outcomes for patients with primary brain and spinal cord tumors.

We offer our patients:

  • Expert evaluation, examinations, tests and imaging
  • State-of-the-art neurosurgery and radiation therapy
  • Therapies based on the genetic characteristics of your specific tumor
  • Consultations and treatments at the Clinic are free-of-charge

The Neuro-Oncology Clinic is located at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.

This is a joint program of the Center for Cancer Research at the National Cancer Institute and the National Institute of Neurological Disorders and Stroke.

Our Mission

The Neuro-Oncology Branch (NOB) is a trans-institutional initiative that launched in 2000. NOB is sponsored by both the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke (NINDS). Our mission is to develop novel diagnostic and therapeutic agents for patients with primary central nervous system tumors. The branch's strategic direction is founded on the belief that the continued application of the traditional and largely empiric approach to cancer drug development that has dominated oncology for three decades will likely result in only small, incremental progress in the treatment of patients with malignant gliomas.

Meaningful advances in patient outcomes will more likely result from therapeutic approaches based on a greater understanding of glioma genetics and biology with the subsequent application of that understanding toward individualized and targeted treatments for patients based on their specific tumor characteristics. Additionally, clinical investigations will incorporate tools to measure the impact of the disease on patient function.  This will typically include measures of symptom burden, quality of life, and cognitive function.

Although we understand that the idea of "personalized medicine" will only be fully realized through the engagement of the entire cancer research and cancer care enterprise, the NOB functions under the premise that within the protected clinical environment and immense scientific freedom of the NIH intramural program, we are ideally situated to build a small prototype of a biology-driven, individualized, patient-centric rational therapeutics program.

Patients and Families

NOB_Patient_ClinicThe diagnosis of a brain or spine tumor often causes many emotions. Reactions can range from denial and shock to anger and confusion. This can seem overwhelming and many patients and families feel like they do not know where to start.

We focus on you.  The National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, is America's research hospital. Our physicians and staff understand what you are feeling and your needs. Our team  provides you with a comprehensive plan that, together with your physician at home, will ensure you get the best treatment possible. 

Patient Resources

Learn more about our multidisciplinary approach to patient care, ways we help patients and their families deal with the physical and emotional facets of this disease and patient education resources.

Follow us on Twitter @NIHBrainTumor to see the latest in brain in spine cancer research, care, and treatment.

Join our Facebook page, NCI-CONNECT Community, to connect with other patients and caregivers.

Make an Appointment

The diagnosis of a brain or spine tumor can be an overwhelming experience; many patients feel it is urgent to get started with their care. Our support team will coordinate all your NIH appointments and travel. We also believe strongly in collaborating with your treating physician (with your permission) to form your "expert care team."

Special Update

Our neuro-oncology clinic is changing normal operating procedures due to the novel coronavirus (COVID-19). 

  • If you are scheduled for an appointment within the next 30 days, you will receive a phone call from a patient care coordinator or health care provider to discuss your visit and what to expect.
  • If you need to schedule an appointment, your health care provider should contact us first.

Your care and safety remain our top priority and we appreciate your understanding during this time of continuous change. You can contact us at or call 1-866-251-9686 or 240-760-6010 with your questions or concerns.

Follow @NIHBrainTumor for updates.

- Posted March 20, 2020

Before your first visit, we will ask you to provide medical records, CDs with (MRIs, CTs, PET) scans and a list of medications.

What are the costs?

  • Consultations are free-of-charge. 
  • After a patient is accepted on a study, treatments, tests and other services at the NIH are also free.
  • NIH does not cover expenses for medical services at other facilities.
  • Patients and their families can focus on treatment instead of cost.

Where is the clinic located?

  • On the NIH campus in Bethesda, Maryland, approximately 8 miles north of Washington, D.C.
  • The Brain Tumor Clinic is on the 13th floor of the Magnuson Clinical Center (Building 10).
  • Visitor information is available at NIH Clinical Center - Access and Directions (View Map).

Learn more...

Healthcare Providers

Candidates for consultation with the Neuro-Oncology Branch healthcare team include patients:

  • with newly diagnosed or recurrent primary tumors of the CNS
  • without a formal diagnosis but with radiographic findings that are concerning for a CNS tumor

Contact us: or 1-866-251-9686 (toll-free) or 240-760-6010

We require a medical summary, relevant radiographic scans (MRI, CT, PET), pathology report, and additional materials as indicated.

With the patient’s permission, we keep their primary physician fully informed and involved in their care. After consultation, the Neuro-Oncology Branch physician (or nurse practitioner) will contact the patient's primary physician to coordinate care and follow-up plans.


Brain Tumor Trials Collaborative

The mission of the Brain Tumor Trials Collaborative (BTTC) is to develop and perform state-of-the-art clinical trials in a collaborative and collegial environment, advancing treatments for patients with brain tumors, merging good scientific method with concern for patient well-being and outcome.


  • About

    The BTTC was created in 2003 as a network of medical centers with the expertise and the desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors. This network of institutions allows patients across a broad geographic range to participate in cutting-edge clinical trials and more rapidly determine the benefits of various therapies.

  • BTTC Clinical Trials

    The current treatment of malignant gliomas, the most common brain tumor in adults, remains challenging and less effective than desired. The BTTC has several trials that are either open or in development. These trials hope to deliver results that provide a more effective treatment therapy in controlling the tumor and increasing survival.

  • BTTC Doctors and Institutions

    Each of the participating BTTC institutions are committed to discovering new and effective therapies for the treatment of patients with brain tumors with compassion and understanding. The doctors who are participating in the BTTC are experts in their respective fields.

Comprehensive Oncology Network Evaluating Rare CNS Tumors

NOB_NCI-CONNECTNCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) aims to advance the understanding of rare adult central nervous system (CNS) cancers by establishing and fostering patient-advocacy-provider partnerships and networks to improve approaches to care and treatment.

Primary CNS cancers are tumors that start in the brain and spinal cord. They account for less than 2% of all cancers diagnosed a year in the United States, with over 130 different types. Although all primary adult CNS tumors can be considered rare, NCI-CONNECT is starting with 12 types, each with less than 2,000 people diagnosed a year.

View NCI-CONNECT Website

The low incident rate of these 12 tumors means patients and researchers face unique challenges. Patients struggle to find expert care and treatments. Researchers have limited resources to study the disease and develop new therapies.

NCI-CONNECT intends to address these challenges and unmet needs by connecting patients, providers, researchers and community organizations to work in partnership.

NCI-CONNECT selected rare adult CNS tumor types:

  • Atypical Teratoid Rhabdoid Tumor (ATRT)
  • Choroid Plexus Tumors
  • Diffuse Midline Gliomas
  • Ependymoma
  • Gliomatosis Cerebri
  • Gliosarcoma
  • Medulloblastoma
  • Meningioma (High Grade)
  • Oligodendroglioma / Anaplastic Oligodendroglioma
  • Pineal Region Tumors
  • Pleomorphic Xanthoastrocytoma / Anaplastic Pleomorphic Xanthoastrocytoma
  • Primitive Neuro-Ectodermal Tumors


NCI-CONNECT has a number of studies that are open for adult patients with rare central nervous system cancers. Check back as we plan to add more.

View NCI-CONNECT Studies

Receive Updates

Receive the latest news in rare adult central nervous system cancer research, care, and treatment.

Connect with Others

Join our Facebook page, NCI-CONNECT Community, to connect with other patients and caregivers.

Contact us: or call (240) 760-6530


NCI-CONNECT is a program within the Rare Tumor Patient Engagement Network (RTPEN), an initiative supported by the National Cancer Moonshot. RTPEN aims to advance research and discover new treatments for rare tumors through a collaborative network of national and international institutions that will provide expertise, personalized health care and education to patients with rare tumors.

NCI-CONNECT as part of RTPEN focuses on rare central nervous system tumors and is managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch.

Brain and Spine Cancer Research

With support from the investigators in the Neuro-Oncology Branch (NOB), we have developed robust programs addressing critical areas of brain and spine cancer research. Our investigators translate laboratory findings into clinical trials which are designed to assess whether a treatment is working and what the impact is on the patient. Each of the laboratory programs have the same goal – to improve brain and spine cancer patient care and outcomes. 

Clinical Research Program

Led by Mark Gilbert, M.D. and Terri Armstrong, Ph.D., this program encompasses a growing portfolio of therapeutic brain and spine cancer clinical trials as well as a series of complementary non-therapeutic studies. The infrastructure that has been developed for clinical research has enabled our investigators to launch studies including phase 0 studies using both microdialysis techniques as well as post-treatment tumor resection to determine tumor drug delivery, phase I studies with pharmacokinetics and pharmacodynamics, and single arm phase II studies. Larger scale clinical trials are being done in the Brain Tumor Trials Collaborative and the NCI-CONNECT Clinical Trials Network, both led by the NOB. Notably, patient outcomes measures are integrated into each clinical trial, complementing ongoing work in the Patient Outcomes Program. 

Patient Outcomes Program

Led by Terri Armstrong, Ph.D., this program is focused on implementing outcomes measures that assess brain and spine cancer patients during the course of their disease. Utilizing the Natural History Study with longitudinal collection of clinical characteristics, Patient Reported Outcomes measures to learn cancer risk information, and biologic samples including germline DNA for single nucleotide polymorphisms are collected for evaluation. Dr. Armstrong is also developing preclinical models for treatment-related toxicities including radiation-induced somnolence which may have an association with polymorphisms of select CLOCK genes.

Translational Research Program

Led by Jing Wu, M.D., Ph.D., this program is focused on the development of brain and spine cancer clinical trials that have strong preclinical science and rationale, enabling the clinical trial to be hypothesis-based with strong correlative biology. Studies with the novel targeted agent, TG02, led to the creation of a successful phase I trial. This program is also investigating the malignant transformation and hypermutation that occurs in a subset of patients harboring IDH-mutated gliomas. This translational research complements the work by Dr. Mioara Larion and the Cancer Metabolism Research Program, translating preclinical models and imaging biomarkers to clinical trials. 

Immunology Program

Initially led by Mark Gilbert, M.D., this program has recently transitioned its leadership to Masaki Terabe, Ph.D., and is focused on various aspects of translational and basic immunology, such as examining the biology of NK-T cells, potent mediators of immune response, in brain and spine cancers. These topics include:

  • Developing techniques to assess the immune phenotype of brain and spine tumors
  • Patient immunocompetence and metrics of peripheral response to immune modulators
  • Evaluating the impact of treatment agents such as chemotherapy and corticosteroids on immune reactivity
  • Achieving a better understanding of the mediators of an effective immune response such as immune cell trafficking
  • Chemokine production in the umor microenvironment 

The Cancer Stem Cell Biology Program

Led by Zhengping Zhuang, M.D., Ph.D., this program focuses on his longstanding interest and expertise in evaluating hypoxia and pseudohypoxia as well as the role of HIF2α abnormalities in brain and spine cancer biology. The ongoing research is focused on understanding the functional impact of the genetic changes that may uncover early disease states and potential therapeutic opportunities. 

Molecular and Cell Biology Program

Led by Chunzhang Yang, Ph.D., this program is focused on the biologic impacts of cancer-associated IDH mutations to uncover selective vulnerability of brain and spine cancers. These investigations have demonstrated that DNA repair pathways are compromised due to the effects of the IDH mutation and that Nrf2-mediated metabolic pathways, such as glutathione de-novo synthesis, support IDH-mutated cells by relieving metabolic stress and oxidative damage. These studies may have a direct link to clinical research as Dr. Jing Wu is developing a robust therapeutic program for patients with IDH-mutant tumors. 

Cancer Metabolism Program

Led by Mioara Larion, Ph.D., this program is studying IDH-mutant gliomas, given the impact that this mutation has on tumor metabolism. Her investigations are exploring the impact of IDH mutations on cellular requirements for carbon sources, lipid metabolism at the molecular, organelle, and cellular levels as well as preclinical development of hyperpolarized MRI using 13C substrates to measure in vitro metabolic flux. Her research compliments the cell biology-focused research by Dr. Chunzhang Yang and the translational and clinical research on IDH-mutant tumors being performed by Dr. Jing Wu.

Training Programs

NOB_TrainingJob Vacancies

The Neuro-Oncology Branch (NOB) Clinic has various job vacancies. The Neuro-Oncology Clinic is comprised of a multidisciplinary team of physicians, other healthcare providers, and scientists who are dedicated to developing new therapies and improving outcomes for patients with primary brain and spinal cord tumors. Click here to view current openings.

Clinical Fellowship

This is a joint program with the Neuro-Oncology Program at the Johns Hopkins Hospital in Baltimore, MD.  The goal is to prepare neurologists, medical oncologists, radiation oncologists and neurosurgeons for research careers in neuro-oncology.

Training includes:

  • Formal coursework in pharmacology and clinical research methodology, 
  • Academic biweekly conferences
  • Patient management from a pool of more than 2,000 brain tumor patients who are seen each year in our Brain Tumor Clinic

Trainees will participate in developing and implementing clinical trials for adult brain tumor therapeutics. Fellows also have the opportunity to attend national scientific meetings and are mentored in pursuit of their clinical, basic, and translational brain tumor research interests. 

Click here for more information or to submit an application. For further questions, email

Clinical Elective

The National Institutes of Health (NIH) Clinical Electives Program emphasizes the important connection between research and patient care in neuro-oncology. Students participate in inpatient and outpatient evaluation of patients, learn about the conduct of clinical research trials, observe surgical procedures, attend clinical care and research conferences, and participate in weekly clinical and laboratory meetings. Students will participate in the workup, evaluation, and planning of treatment for patients they see.

Objectives include:

  • Prepare trainees to deliver state-of-the-art diagnostic and consultative services in the field of neuro-oncology
  • Introduce trainees to research in neuro-oncology and to inspire them to pursue a lifelong career of academic inquiry

The elective affords an opportunity to gain an understanding of the techniques of clinical research, as well as experience in the evaluation and treatment of patients with diseases of the CNS. Although laboratory research is closely coordinated with clinical activities in the NOB, the student will not engage in laboratory investigations during this course.

Click here for more information or to submit an application. For further questions, email

Clinical Base Training

The NIH Clinical Center offers an extensive range of clinical research training to help prepare the next generation of clinician-scientists. The innovative curriculum includes courses in pharmacology, principles and practice of clinical research and bioethics.

Training programs include:

  • Summer internship program
  • Internships throughout the year
  • Undergraduate scholarship program
  • Intramural research training program
  • Postdoctoral training program
  • Research fellowship
  • Clinical fellowship

Click here for more information or to submit an application. For further questions, email

Summer Internship Program

Trainees accepted into one of the NIH Summer Internship programs and working in the Neuro-Oncology Branch can participate in the NOB’s Translational Research Immersion Program (NOB-TRIP). This program is designed to immerse interns in the patient-centered research conducted within the NOB. Interns will have the opportunity to observe and engage with clinical and laboratory professionals that lead clinical, translational, and basic research. This 10-week program consists of five structured areas of educational focus.

Training includes:

  • Didactic lectures
  • Weekly seminars with the NOB Chief on research rigor and career planning
  • Cross-focus observational experiences
  • Integration of wellness
  • Mentoring in training and public speaking

Opportunities are available for high school, college, grad school and professional school students through the NIH Summer Internship Program in Biomedical Research program.

Click here for more information or to submit an application. For further questions, email



Glioblastoma Survivor, Bob, Finds Hope at the NIH

July 1, 2020

Bob was diagnosed with glioblastoma in 2015. A previously active bicyclist and outdoor enthusiast, read how he made many lifestyle changes to accommodate his needs as he underwent treatment. Learn more...

BTTC Colleagues Integrated into Weekly Tumor Board

June 25, 2020

In a continuing effort to increase collaboration, the weekly Neuro-Oncology Tumor Board held at the NIH is now inclusive of BTTC doctors at remote institutions to improve patient care. Learn more... 

Andrew, An Astrocytoma Survivor Building a New Life

June 19, 2020

Andrew, an astrocytoma survivor, visits the Neuro-Oncology Branch regularly for treatment advice from our experienced neuro-oncology physicians and nurses. Read about his experience with our clinic and new outlook on life after diagnosis. Learn more... 

Telehealth: What You Need to Know About a Virtual Doctor Visit

June 19, 2020

Neuro-oncology experts share what telehealth is, the benefits and limitations, how to prepare and what to expect during and after your visit. Learn more... 

Spotlight on Matt Lindsley

May 26, 2020

Matt Lindsley, a research nurse at the Neuro-Oncology Branch, also serves as a Lieutenant in the U.S. Public Health Service. His passionate service to the NOB clinical trial patients is integral to our branch's mission. Learn more... 

Celebrating Nurses Week

May 12, 2020

We highlight the tireless contribution our nurse practitioners, research nurses and nurse-scientists make to provide the best care for our brain and spine tumor patients. Learn more... 

Advances in Clinical Care and Research 

April 29, 2020

Our Neuro-Oncology Branch is advancing care and treatment for people with brain and spine tumors through collaborative scientific workshops, research discovers, and successful clinical trials. Learn more... 

New Strategy for Treating Brain Tumors with Mutations in Etabolic Enzymes​

April 10, 2020

Dr. Chunzhang Yang and his team uncover the molecular effects of IDH mutations in gliomas, including stress, reactive oxygen species and changes in a protein named NRF2. The group also explored how a small molecule inhibitor for NRF2 can make glioma cells more responsive to therapy in preclinical mouse models. Learn more... 

Tracking Patient Outcomes to Improve Clinical Trials

March 6, 2020

In collaboration with leaders in the field, Dr. Terri Armstrong published a paper outlining the importance of tracking patient outcomes in clinical trials. Including these patient-reported outcomes can help physicians better understand the impact of the tumor on the patient and their lives. Learn more... 

Women Scientist Appreciation Month

March 1, 2020

In celebration of International Women and Girls In Science Day, we celebrated female scientists, physicians and mentors in the Neuro-Oncology Branch that strive everyday to make advances in ground-breaking research for brain and spine tumor patients. Learn more... 

Exploratory Adapatation Explains How Glioblastoma Cells Adapt and Survive

February 5, 2020

Dr. Orieta Celiku and Dr. Mark Gilbert publish an article on the concept of exploratory adaptation in glioblastoma. Using bioinformatics and mathematical modeling, they have found tools to explain how glioblastoma cells may adapt to survive in stressful conditions. Learn more... 

Celebrating National Mentoring Month

January 31, 2020

We celebrate our impactful mentors in the Neuro-Oncology Branch for National Mentoring Month. Our postdoctoral fellows share their love for science and how their mentors have made their experience at NIH more rewarding. Learn more... 

FDA Grants Orphan Drug Designation to Zotiraciclib for the Treatment of Glioma​

January 9, 2020

Dr. Jing Wu's investigational drug, zotiraciclib, receives orphan drug approval by the FDA for the treatment of glioma, which comprises up to 30% of all brain and central nervous system tumors. Learn more... 

Why a Precise Diagnosis is Vital to Treat Brain and Spine Tumors​

October 10, 2019

NCI neuropathologist Dr. Kenneth Aldape is using the latest technologies to precisely diagnose brain and spine tumors. He shares his techniques and why they’re important to precision medicineLearn more... 

Clinical Trial Tests New Drug for Recurrent Ependymomas

May 28, 2019

Ependymomas are rare tumors that arise in the fluid-filled cavities in the brain and spinal cord. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature. Learn more... 

New Strategy for Treating Brain Tumors with Mutations in Metabolic Enzymes​

February 20, 2019

Dr. Chun Zhang Yang studies how IDH-mutant gliomas and reactive oxygen species (ROS) can allow glioma cells to become malignant and survive. Learn more... 

Clinical Trial Studies Antitumor Effect of Sunitinib in Central Nervous System Sarcomas

February 4, 2019

A new clinical trial studying the cancer drug sunitinib for recurrent gliosarcoma and previously treated sarcomas of the CNS, which comprises the brain and spinal cord. Learn more...

Targeting Survival: Living Well with Brain Cancer in the Era of Precision Treatments

November 1, 2018

Dr. Mark Gilbert outlines his work in immunotherapy brain cancer research at the Cooperative Trials Group for Neuro-Oncology (COGNO) 2018 Learn more...

See Brain Cancer as More Than Just the Sum of Biology

September 26, 2018

Dr. Terri Armstrong shares how neurological symptoms, as well as biological changes in cells and tissues, contribute to the disease’s characteristics. Learn more...

NCI-CONNECT Rare Brain and Spine Tumor Network Website Launches

September 24, 2018

New network fosters patient-advocacy-provider partnerships and networks to improve care and treatment of rare brain and spine tumors. Learn more...

Can Immunotherapy Suceed in Glioblastoma?

May 24, 2018

Despite continued efforts to develop new therapies for glioblastoma, none have been able to improve how long patients live appreciably. Despite some setbacks, researchers are hopeful that immunotherapy might be able to succeed where other therapies have not. Learn more...

Rare Cancer Moonshot Project

December 6, 2017

Dr. Mark Gilbert shares information about the new moonshot project focusing on rare brain tumors: bringing together scientists and clinicians while closely following the patient experience. Learn more...

Adding Immune-Based Treatments to Standard Glioblastoma Therapy

October 11, 2017

This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma. Learn more...

Clinical Trial Aims to Study Immunotherapy for Central Nervous System Tumors

August 23, 2017

A new clinical trial aims to determine whether nivolumab, an immune checkpoint inhibitor, can improve control of cancer for patients with several types of tumors of the central nervous system (CNS). The CNS is composed of the brain and spinal cord and the cause of most CNS tumors in adults is unknown. Learn more...

Glioblastoma – Unraveling the Threads

August 3, 2017

Progress against the brain cancer glioblastoma has been slow. Drs. Gilbert and Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that. Learn more...

Clinical Trial Explores New Glioblastoma Treatment Regimen

May 22, 2017

On average, a patient with glioblastoma lives for only about a year after diagnosis. In a new clinical trial, CCR researchers will test whether a combination of a vaccine made from the patient’s tumor with another immunotherapy treatment can increase survival rates. Learn more...

PARP Inhibitors May be Effective in Brain, Other Cancers With IDH Mutations

April 24, 2017

Two separate studies have revealed new insights into the function of genetic mutations commonly found in a form of brain cancer as well as several other cancers and, in the process, identified a potential new treatment strategy. Learn more…

Brain Cancer’s Cholesterol Addiction May Offer New Strategy

December 26, 2016

Brain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival. Learn more…

Study Tests the Safety and Efficacy of Combination Therapy in Adults with Astrocytoma and Glioblastoma

December 2, 2016

A two-part clinical trial of a multikinase inhibitor plus chemotherapy in patients with two types of brain tumors is enrolling. The study will be open to patients with anaplastic astrocytoma, an uncommon malignant brain tumor that develops from star-shaped brain cells called astrocytes and glioblastoma, the most common and aggressive form of astrocytoma. Learn more…

Breaching the Blood–Brain Barrier

August 10, 2016

Despite the development of gene sequencing and targeted cancer treatments se advances, the biological equivalent of a brick wall — the blood–brain barrier — has remained almost impenetrable. Dr. Sadhana Jackson shares how researchers are on a quest to breach the blood-brain barrier to treat brain cancer. Learn more…

Clinical Trial to Study Long-Term Progression of Brain and Spine Cancers

August 8, 2016

Dr. Mark Gilbert describes an ambitious new clinical trial that, for the first time, will study the long-term progression of brain and spine cancers. The 10,000 atient trial is the largest of its kind and will follow patients throughout the course of their disease. In addition to identifying optimal treatments for common brain and spine cancers, the study focuses on treatment discovery for rare, overlooked cancers. Learn more…

Trials Produce Practice-Changing Results for Brain Cancer

June 9, 2016

Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival. Learn more…

With Immunotherapy, Glimmers of Progress Against Glioblastoma

March 8, 2016

Researchers who specialize in brain cancer are optimistic about immunotherapy’s prospects for improving outcomes in patients with this aggressive form of brain cancer. Learn more…

Genome Study Links Misfolded DNA to Brain Tumors

January 12, 2016

Changes in the packaging of DNA in the cell nucleus may activate growth-promoting genes that cause cancer. Learn more…

Patient with Brain Tumor Responds Dramatically to Targeted Therapy

December 3, 2015

A patient with a papillary craniopharyngioma saw his tumor shrink more than 80 percent after treatment with a targeted drug that inhibits a mutant form of the BRAF protein. Learn more…

Genomic Underpinnings of Brain Tumors Expanded

June 10, 2015

TCGA researchers analyzed nearly 300 cases of diffuse low- and intermediate-grade gliomas, which together comprise lower-grade gliomas. LGGs occur mainly in adults and include astrocytomas, oligodendrogliomas and oligoastrocytomas. Learn more…

"Flipping the Switch": An Interview with Dr. Mark Gilbert, Chief of NIH’s Neuro-Oncology Branch

February 18, 2015

In November 2014, Mark Gilbert, M.D., became chief of the NIH Neuro-Oncology Branch. NCI's Dr. Mark Gilbert discusses new developments in neuro-oncology and the priorities of the Neuro-Oncology Branch. Learn more…

Neuro-Oncology Branch Welcomes Dr. Mark Gilbert as New Branch Chief

October 30, 2014

Dr. Gilbert's vision is to build a highly collaborative, robust translational research program centered on finding treatments for brain and other central nervous system tumors.  Learn more about Dr. Gilbert…

A New "America's Neuro-Oncologist" at the National Cancer Institute

October 28, 2014

"Having had the pleasure of working together with Dr. Gilbert on a number of projects in recent years, I can attest to his expertise, professionalism, and dedication to the brain tumor community, said David Arons, Chief Public Policy and Advocacy Officer, National Brain Tumor Society. "Dr. Gilbert is an excellent fit, and we look forward to working with him as he develops his programs and priorities for the Neuro-Oncology Branch moving forward."  Read more…